K. Baeten

发表

Prognostic and predictive value of circulating tumor cells and CXCR 4 expression as biomarkers for a CXCR 4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer : exploratory analysis of a phase II study

R. Salgia, M. Connelly, D. Spigel, 2017 .

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

G. Follows, S. Voloshin, A. Kater, 2022, NEJM Evidence.

Tracking of myelin-reactive T cells in EAE animals using small particles of iron oxide and MRI.

P. Adriaensens, J. Gelan, I. Lambrichts, 2010 .

Abstract P2-02-17: T-DM1 in HER2-negative metastatic breast cancer patients with HER2-amplified circulating tumor cells: Current status of the CirCe T-DM1 phase II trial

M. Espié, M. Bollet, G. Romieu, 2016 .

Peripheral blood but not synovial fluid natural killer T cells are biased towards a Th1-like phenotype in rheumatoid arthritis

P. Geusens, L. Linsen, P. Stinissen, 2005, Arthritis research & therapy.

Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation

C. Almici, B. Bruno, R. Verardi, 2017, Bone Marrow Transplantation.

Identification of Protein Networks Involved in the Disease Course of Experimental Autoimmune Encephalomyelitis, an Animal Model of Multiple Sclerosis

J. Robben, S. Plaisance, N. Hellings, 2012, PloS one.

Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer

H. Scher, M. Fleisher, D. Danila, 2016, European urology.

Unlocking the Potential of Saliva-Based Test to Detect HPV-16-Driven Oropharyngeal Cancer

I. Frazer, L. Kenny, C. Punyadeera, 2019, Cancers.

First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study

G. Follows, A. Kater, L. Ysebaert, 2021, Blood.

Counting circulating endothelial cells in allo-HSCT: an ad hoc designed polychromatic flowcytometry-based panel versus the CellSearch System

C. Almici, D. Russo, B. Bruno, 2019, Scientific Reports.

Early CTC decline as a biomarker of response to treatment in castration-resistant prostate cancer (CRPC): Analysis of the COU-AA-301 and IMMC38 trials.

H. Scher, J. Bono, D. Olmos, 2015 .

Detailed Visualization of the Functional Regions of the Rat Pituitary Gland by High‐Resolution T2‐Weighted MRI

L. Vanormelingen, P. Adriaensens, J. Gelan, 2010, Anatomia, histologia, embryologia.

Oral HPV16 Prevalence in Oral Potentially Malignant Disorders and Oral Cavity Cancers

I. Frazer, L. Walsh, M. Batstone, 2020, Biomolecules.

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study

Sameera R. Wijayawardana, Ravi Salgia, R. Salgia, 2017, Investigational New Drugs.

Detection of Lung Cancer through Metabolic Changes Measured in Blood Plasma

C. Dooms, P. Adriaensens, Z. Shkedy, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Visualisation of the kinetics of macrophage infiltration during experimental autoimmune encephalomyelitis by magnetic resonance imaging

P. Adriaensens, J. Gelan, N. Hellings, 2008, Journal of Neuroimmunology.

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

G. Follows, A. Howes, A. Kater, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Counting circulating endothelial cells in allo-HSCT: an ad hoc designed polychromatic flowcytometry-based panel versus the CellSearch System

C. Almici, D. Russo, B. Bruno, 2019, Scientific Reports.

Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.

G. Follows, A. Howes, A. Kater, 2023, The Lancet. Oncology.